Cronos Group Inc.
TSX:CRON.TODrug Manufacturers - Specialty & Generic
-$0.01 today
- Market cap
- $1.67B
- Beta
- 1.25
- P/E (TTM)
- -488.1
- EPS (TTM)
- -$0.01
Volume 0.15M
Average 0.19M
CRON.TO Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Cronos Group Inc.TSX: CRON.TO
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $1.84M (cash outflow) fell 88.0% year over year, behind the -53.1% change in trailing-twelve-month capital expenditures. Sequentially, it fell 14.6% from the prior quarter. Over 3 fiscal years it compounded at +73.2% a year.
Context
- Capital expenditures amounted to 17.5% of revenue in FY2025, up 6.3 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -88.0% toward the trailing-twelve-month pace of -53.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (26.17M) USD
- Year-over-year change
- -98.9%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (26.17M) | -98.9% |
| FY2024 | 2024-12-31 | (13.15M) | -284.3% |
| FY2023 | 2023-12-31 | (3.42M) | +32.0% |
| FY2022 | 2022-12-31 | (5.03M) | +59.0% |
| FY2021 | 2021-12-31 | (12.26M) | — |
Capital Expenditures vs competitors
How CRON.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -53.1% is the lowest of 6, against a peer median of +21.1%.
- Capital expenditures amounts to 7.8% of revenue for CRON.TO, versus a peer median of 4.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | CA$118.65M CAD | -28.6% | +35.2% | 10.7% | |
| LTM Jun 2026 | CA$90.4M CAD | +72.2% | +0.1% | 4.6% | |
| LTM Feb 2026 | $32.82M USD | -7.1% | -1.1% | 3.8% | |
| LTM Mar 2026 | CA$32.64M CAD | +62.7% | +63.3% | 2.2% | |
| LTM Mar 2026 | CA$29.37M CAD | +21.1% | -58.0% | 5.8% | |
| LTM Mar 2026 | $12.43M USD | -53.1% | +73.2% | 7.8% | |
| Peer median (excluding CRON.TO) | — | +21.1% | +0.1% | 4.6% | |
Competitors are the stored peer set for CRON.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (397.2M) | (168.73M) | (74.55M) | 40.02M | (9.61M) |
| Depreciation & Amortization | 15.4M | 13.12M | 8.11M | 9.34M | 14.48M |
| Deferred Income Tax | 222.22M | 0 | 43.32M | 0 | 0 |
| Stock-Based Compensation | 10.15M | 15.12M | 8.77M | 8.7M | 0 |
| Change in Working Capital | (2.01M) | 20.66M | (26.47M) | (311K) | (35.02M) |
| Accounts Receivables | (13.16M) | (2.71M) | 9.21M | (2.51M) | (26.2M) |
| Inventory | 11.57M | (7.22M) | 7.4M | 7.42M | (10.58M) |
| Accounts Payables | (2.37M) | (863K) | (773K) | (7.45M) | 1.13M |
| Other Working Capital | 1.97M | 31.45M | (42.3M) | 2.24M | 636.96K |
| Other Non-Cash Items | (2.18M) | 30.89M | (2.01M) | (38.9M) | 56.47M |
| Operating Cash Flow | (153.62M) | (88.95M) | (42.84M) | 18.84M | 26.32M |
| Capital Expenditures | (12.26M) | (5.03M) | (3.42M) | (13.15M) | (26.17M) |
| Acquisitions (Net) | (1.12M) | 0 | 724K | 5.99M | 2.9M |
| Purchases of Investments | (230M) | (271.38M) | (608.25M) | 0 | (59.44M) |
| Sales of Investments | 215.3M | 268.87M | 532.84M | 185.82M | 5.15M |
| Other Investing Activities | (819K) | 5.7M | 18.61M | (4.25M) | 0 |
| Investing Cash Flow | (28.9M) | (1.84M) | (59.5M) | 175.15M | (77.9M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 15.73K | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (2.85M) | (1.03M) | 0 | (9.91M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (13.46M) | (42.36K) | (2.47K) | (1.23M) | (10.34M) |
| Financing Cash Flow | (13.44M) | (2.9M) | (1.03M) | (1.23M) | (20.25M) |
| Effect of Forex Changes | 4.91M | (28.64M) | 8.01M | (3.25M) | (37.24M) |
| Net Change in Cash | (191.05M) | (122.33M) | (95.35M) | 189.51M | (109.07M) |
| Free Cash Flow | (165.88M) | (93.98M) | (46.26M) | 5.69M | 151.61K |
Cronos Group Inc.
TSX:CRON.TO
Intrinsic Alpha fair value
Locked
Current Price
$4.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.